Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > HLVX HilleVax > Key Indicators
HLVX HilleVax
13.010
+1.160+9.79%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q1)2021/03/31(FY)2020/12/31
Financial Ratios
Efficiency Ratios TTM
ROA
-- -104.441% 79.89% -83.734% -- -- -- -416.436%
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
Current Ratio
-- 0.3949 255.41% 0.5475 -- -- -- 0.1541
Quick Ratio
-- 0.3932 292.29% 0.5469 -- -- -- 0.1394
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
CEO: Hershberg M.D., Ph.D., Robert M.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top